Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck

International Journal of Clinical Oncology

Volumn 9, Issue 3, 2004, Pages 161-166

  Tsukuda, Mamoru ^a   Mikami, Yasukazu ^a   Tanigaki, Yuji ^a   Katori, Hideaki ^a   Horiuchi, Choichi ^a   Ikeda, Yoichi ^a   Taguchi, Takahide ^a   Ono, Machiko ^a   Yoshida, Takahumi ^a   Sakuma, Yasunori ^a   Aikoh, Ken ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

5 Fluorouracil; Combination chemotherapy; Docetaxel Cisplatin; Head and neck carcinoma

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CREATININE; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; UFT;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; NASOPHARYNX CANCER; NEPHROTOXICITY; NEUTROPENIA; OROPHARYNX CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; VOMITING;

EID: 3142517815     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-004-0390-8     Document Type: Article

References (29)

1. Munro AJ (1995) An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 71:83-91
2. El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 14:838-887
3. Hughes RS, Frenkel EP (1997) The role of chemotherapy in head and neck cancer. Am J Clin Oncol 20:449-461
4. Veterans Affairs Laryngeal Cancer Group (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-1689
5. Lefebvre JL, Chevalier D, Luboinski B, et al. (1996) Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 88:890-898
6. Browman GP, Hodson DI, Mackenzie RJ, et al. (2001) Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 23:579-589
7. Dimery IW, Hong WK (1993) Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 85:95-111
8. Clark JR, Busse PM, Norris CM, et al. (1997) Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 15:3100-3110
9. Schöffski P, Catimel G, Planting AST, et al. (1999) Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group. Ann Oncol 10:119-122
10. Dreyfuss AI, Clark JR, Norris CM, et al. (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14:1672-1678
11. Kelland LR, Abel G (1992) Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450
12. Hill BT, Whelan RDH, Shellard SA, et al. (1994) Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12:169-182
13. Fujii H, Ebihara T, Tsukuda M, et al. (2002) Phase I/II study of Taxotere (TXT) and cisplatin (CDDP) in patients with head and neck cancer (in Japanese). J Jpn Soc Cancer Ther 37:516 (abstract PO32-3)
14. Furukawa S (1992) Combination chemotherapy of CDDP and 5-FU in head and neck squamous cell carcinome (in Japanese). Yokohama Med Bull 43:55-70
15. Ishikawa T, Ali-Osman F (1993) Glutathione-associated cisdiamminedichloro-platinum (II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268:20116-20125
16. Furukawa S, Tsukuda M, Mochimatsu I, et al. (1994) Modified combination chemotherapy of cisplatin and 5-fluorouracil in squamous cell carcinomas of the head and neck. Auris Nasus Larynx 21:181-185
17. Esaki T, Nakano S, Masumoto N, et al. (1996) Schedule-dependent reversion of acquired cisplatin resistance by 5-fluorouracil in a newly established cisplatin-resistant HST-1 human squamous carcinoma cell line. Int J Cancer 65:479-484
18. Tsukuda M (2000) Recent regimen of chemotherapy for advanced head and neck carcinomas (in Japanese). Jpn J Cancer Chemother 27:341-347
19. Inuyama Y, Kida A, Tsukuda M, et al. (2001) Late phase II study of S-1 in patients with advanced head and neck cancer (in Japanese). Jpn J Cancer Chemother 28:1381-1390
20. Tsukuda M, Miyake H (2000) Maintenance chemotherapy with UFT for head and neck carcinoma. Oncology 14 (10, Suppl 9):93-95
21. Inuyama Y, Kataura A, Togawa K, et al. (1999) Late phase II clinical study of RP 56976 (docetaxel) in patients with advanced/recurrent head and neck cancer (in Japanese). Jpn J Cancer Chemother 26:107-116
22. Baur M, Kienzer HR, Schweiger J, et al. (2002) Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma. Cancer 94:2953-2958
23. Glisson BS, Murphy BA, Frenette G, et al. (2002) Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20:1593-1599
24. Cruz JJ, Fonseca J, Garcia Gomez J, et al. (2002) Randomized phase II, multicenter trial of induction chemotherapy in patients with locally advanced head and neck carcinoma (LA-HNC). Docetaxel plus cisplatin (DP) versus cisplatin plus 5-FU (PF): interim results. Proc Am Soc Clin Oncol 21:231a (abstract 920)
25. Schrijvers D, Van Herpen C, Kerger J, et al. (1999) Phase I-II study with docetaxel (D), cisplatin (C) and 5-fluorouracil (5-FU) in patients (PTS) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 18:394a (abstract 1524)
26. Janinis J, Papadakou M, Panagos G, et al. (2001.) Sequential chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Oncol 24:227-231
27. Posner MR, Glisson B, Frenette G, et al. (2001) Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19:1096-1104
28. Al-Kourainy K, Kish J, Ensley J, et al. (1987) Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59:233-238
29. Pignon JP, Bourhis J, Domenge C, et al. (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 355:949-955